{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:30:45Z","timestamp":1791325845088,"version":"4.3.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Only few studies have analyzed the efficacy of tixagevimab\/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab\/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab\/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44\/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab\/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab\/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.<\/jats:p>","DOI":"10.1186\/s13045-023-01423-7","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:50:27Z","timestamp":1680501027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Passive pre-exposure immunization by tixagevimab\/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6353-2272","authenticated-orcid":false,"given":"Francesco","family":"Marchesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-8297","authenticated-orcid":false,"given":"Jon","family":"Salmanton-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-5953","authenticated-orcid":false,"given":"Caterina","family":"Buquicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-5281","authenticated-orcid":false,"given":"Federico","family":"Itri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-7173","authenticated-orcid":false,"given":"Caroline","family":"Besson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-2073","authenticated-orcid":false,"given":"Julio","family":"D\u00e1vila-Valls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-7165","authenticated-orcid":false,"given":"Sonia","family":"Mart\u00edn-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-7202","authenticated-orcid":false,"given":"Luana","family":"Fianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2266-445X","authenticated-orcid":false,"given":"Laman","family":"Rahimli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8177-2269","authenticated-orcid":false,"given":"Giuseppe","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8583-7501","authenticated-orcid":false,"given":"Federica Irene","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7958-4966","authenticated-orcid":false,"given":"Mariarita","family":"Sciume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-0287","authenticated-orcid":false,"given":"Jorge","family":"Labrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-8836","authenticated-orcid":false,"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5354-5261","authenticated-orcid":false,"given":"Alberto","family":"L\u00f3pez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8982-8079","authenticated-orcid":false,"given":"Nicola S.","family":"Fracchiolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5124-6970","authenticated-orcid":false,"given":"Francesca","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-4901","authenticated-orcid":false,"given":"Emanuele","family":"Ammatuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-2755","authenticated-orcid":false,"given":"Antonella","family":"Cingolani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0932-0345","authenticated-orcid":false,"given":"Daniel","family":"Garc\u00eda-Bordallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7678-0179","authenticated-orcid":false,"given":"Stefanie K.","family":"Gr\u00e4fe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-3407","authenticated-orcid":false,"given":"Yavuz M.","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0924-4629","authenticated-orcid":false,"given":"Michelina","family":"Dargenio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-2554","authenticated-orcid":false,"given":"Tom\u00e1s Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4195-6397","authenticated-orcid":false,"given":"Anna","family":"Guidetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-5311","authenticated-orcid":false,"given":"Tobias","family":"Lahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1490-0678","authenticated-orcid":false,"given":"Esperanza","family":"Lavilla-Rubira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-7004","authenticated-orcid":false,"given":"Gustavo-Adolfo","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1660-4960","authenticated-orcid":false,"given":"Lucia","family":"Prezioso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-0975","authenticated-orcid":false,"given":"Martin","family":"Sch\u00f6nlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0214-3219","authenticated-orcid":false,"given":"Jaap","family":"Van Doesum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4761-075X","authenticated-orcid":false,"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-8949","authenticated-orcid":false,"given":"Ditte Stampe","family":"Hersby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-8668","authenticated-orcid":false,"given":"Ferenc","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7125-7001","authenticated-orcid":false,"given":"Jens","family":"Van Praet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-1440","authenticated-orcid":false,"given":"Verena","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-6024","authenticated-orcid":false,"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5888-7706","authenticated-orcid":false,"given":"Iker","family":"Falces-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-0738","authenticated-orcid":false,"given":"Andreas","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8287-928X","authenticated-orcid":false,"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"key":"1423_CR1","doi-asserted-by":"crossref","unstructured":"Pagano L, Salmanton-Garcia J, Marchesi F, Blennow O, Gomes da Silva M, Glenth\u00f8j A, et al. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey. Blood. 2022;140:2773\u201387.","DOI":"10.1182\/blood.2022017257"},{"key":"1423_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14:168.","journal-title":"J Hematol Oncol"},{"key":"1423_CR3","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1097\/HS9.0000000000000789","volume":"6","author":"J Salmanton-Garcia","year":"2022","unstructured":"Salmanton-Garcia J, Marchesi F, Glenthoj A, Bilgin YM, van Praet J, D\u00e1vila-Valls J, et al. Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine: an EPICOVIDEHA report. Hemasphere. 2022;6:e789.","journal-title":"Hemasphere"},{"key":"1423_CR4","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022;386:2188\u2013200.","journal-title":"N Engl J Med"},{"key":"1423_CR5","unstructured":"European Medicine Agency. Evusheld. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evusheld-epar-product-information_en.pdf. Last accessed 30 Nov 2022."},{"key":"1423_CR6","unstructured":"U.S. Food and Drug Administration. Fact sheet for Patients, Parents And Caregivers Emergency Use Authorization (EUA) of EVUSHELD\u2122 (tixagevimab co-packaged with cilgavimab) for Coronavirus Disease 2019 (COVID-19). https:\/\/www.fda.gov\/media\/154702\/download. Last accessed 30 Nov 2022."},{"key":"1423_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","volume":"40","author":"R Stuver","year":"2022","unstructured":"Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, et al. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022;40:590\u20131.","journal-title":"Cancer Cell"},{"key":"1423_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood.2022018283","volume":"141","author":"JA Davis","year":"2023","unstructured":"Davis JA, Granger K, Roubal K, Smith D, Gaffney KJ, McGann M, et al. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. Blood. 2023;141:200\u20133.","journal-title":"Blood"},{"key":"1423_CR9","doi-asserted-by":"publisher","first-page":"e612","DOI":"10.1097\/HS9.0000000000000612","volume":"5","author":"J Salmanton-Garcia","year":"2021","unstructured":"Salmanton-Garcia J, Busca A, Cornely OA, Corradini P, Hoenigl M, Klimko N, et al. EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID-19. Hemasphere. 2021;5:e612.","journal-title":"Hemasphere"},{"key":"1423_CR10","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.3390\/curroncol29060315","volume":"29","author":"C Owen","year":"2022","unstructured":"Owen C, Robinson S, Christofides A, Sehn LH. A Canadian perspective: monoclonal antibodies for pre- and post-exposure protection from COVID-19 in vulnerable patients with hematological malignancies. Curr Oncol. 2022;29:3940\u20139.","journal-title":"Curr Oncol"},{"key":"1423_CR11","doi-asserted-by":"crossref","unstructured":"Arora P, Kempf A, Nehlmeier I, Schulz SR, J\u00e4ck HM, P\u00f6hlmann S, et al. Omicron\u00a0sublineage\u00a0BQ.1.1\u00a0resistance\u00a0to\u00a0monoclonal\u00a0antibodies. Lancet Infect Dis 2023;23:22\u20133.","DOI":"10.1016\/S1473-3099(22)00733-2"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01423-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:53:11Z","timestamp":1680501191000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01423-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1423"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01423-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was formally approved by the Ethical Committee of Fondazione Policlinico Universitario Agostino Gemelli\u2014IRCCS, Universit\u00e0 Cattolica del Sacro Cuore of Rome with the following registration number: 3226. The study was conducted in compliance with Helsinki Declaration and Good Clinical Practice. The corresponding local ethics committee of each participating institution has approved the EPICOVIDEHA study when applicable. EPICOVIDEHA has been registered at www.clinicaltrials.gov with the identifier NCT04733729. The anonymized data that do not contain any personally identifiable information from any sources implies that the informed consent is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}